Skip to main content

Table 2 Baseline Characteristics

From: Temozolomide and cisplatin in relapsed/refractory acute leukemia

 

N = 20

Age

52 (24–73)

Sex

10M/10F

Performance Status

2 (1–3)

Diagnosis:

 

   AML

15

   ALL

3

   Biphenotypic

2

Number of prior regimens

3 (1–5)

Prior stem cell transplant

3 (1 auto/2 allo)

Prior AHD

6 (5 MDS/1 aplastic anemia)

Cytogenetics:

 

   Good Risk

2 (10%)

   Intermediate Risk

13 (65%)

   High Risk

5 (25%)